RICHARD ALDRICH
CIK 1185039 · last filed 2023-03-06
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$79.91M
Companies
12
Total Filings
101
Lifetime Open-Market Net
$22.50M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted | Director | 0 | $8.37 | $0 | -$1.19M | 20 | 2023-03-06 |
| Tempest Therapeutics, Inc. (MLND) Delisted | Director | 4,687 | $15.90 | $74.5K | $0 | 1 | 2018-12-11 |
| KalVista Pharmaceuticals, Inc. (KALV) Delisted | Director | 934,484 | $27.00 | $25.23M | $4.87M | 5 | 2018-10-05 |
| Tempest Therapeutics, Inc. (OVAS) Delisted | Director | 69,552 | — | — | $8.55M | 37 | 2018-10-02 |
| PTCT | Director | 1,050,104 | $74.52 | $78.25M | $11.11M | 5 | 2015-06-10 |
| VSTM | Director | 273,081 | $6.01 | $1.64M | $270.2K | 23 | 2013-11-12 |
| BIOSPECIFICS TECHNOLOGIES CORP (BSTC) Delisted | 10%+ Owner | 690,309 | — | — | $6.69M | 4 | 2008-11-14 |
| SEQUENOM INC (SQNM) Delisted | 10%+ Owner | 5,872,966 | — | — | $0 | 1 | 2008-07-14 |
| CRIS | 10%+ Owner | 3,125 | $4.97 | $15.5K | -$9.10M | 1 | 2008-04-17 |
| ARADIGM CORP (ARDM) Delisted | 10%+ Owner | 189,210 | — | — | $1.30M | 1 | 2008-01-16 |
| Sirtris Pharmaceuticals, Inc. (SIRT) Delisted | Director | 38,095 | — | — | $0 | 1 | 2007-05-31 |
| LIPID SCIENCES INC/ (LIPD) Delisted | 10%+ Owner | 3,713,962 | — | — | $1.7K | 1 | 2007-03-28 |
Recent Filings · Page 3 of 11
101 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-10-19 | KalVista Pharmaceuticals, Inc. (KALV) Delisted | Buy (P) | +565,065 | $4.87M | EDGAR |
| 2017-10-03 | Tempest Therapeutics, Inc. (OVAS) Delisted | Grant (A) | +7,482 | $0 | EDGAR |
| 2017-09-29 | KalVista Pharmaceuticals, Inc. (KALV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-07-05 | Tempest Therapeutics, Inc. (OVAS) Delisted | Grant (A) | +6,810 | $0 | EDGAR |
| 2017-06-23 | Tempest Therapeutics, Inc. (OVAS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-06-19 | CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-04-04 | Tempest Therapeutics, Inc. (OVAS) Delisted | Grant (A) | +5,681 | $0 | EDGAR |
| 2017-03-27 | KalVista Pharmaceuticals, Inc. (KALV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-01-04 | Tempest Therapeutics, Inc. (OVAS) Delisted | Mixed | +6,944 | $10.6K | EDGAR |
| 2016-11-29 | KalVista Pharmaceuticals, Inc. (KALV) Delisted | Grant (A) | +369,419 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.